Bitopertin Phase 3 Meets Dual EPP Endpoints

Company Disc Medicine Event Type Phase 3 Topline Results (APOLLO) Modality Small molecule; oral GlyT1 inhibitor Asset Bitopertin Target GlyT1 (heme biosynthesis modulation) Disease Area Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) Summary Disc Medicine reported that the randomized Phase 3 APOLLO trial met both…